Comments
Loading...

Monte Rosa Therapeutics

GLUENASDAQ
Logo brought to you by Benzinga Data
$5.95
0.030.51%
At Close: -
$5.95
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Overweight
Highest Price Target1
$22.00
Lowest Price Target1
$11.00
Consensus Price Target1
$16.00

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock, Analyst Ratings, Price Targets, Forecasts

Monte Rosa Therapeutics Inc has a consensus price target of $16 based on the ratings of 8 analysts. The high is $22 issued by UBS on October 13, 2022. The low is $11 issued by Wedbush on September 12, 2024. The 3 most-recent analyst ratings were released by Wedbush, Wells Fargo, and Piper Sandler on September 12, 2024, August 12, 2024, and June 28, 2024, respectively. With an average price target of $14.67 between Wedbush, Wells Fargo, and Piper Sandler, there's an implied 146.50% upside for Monte Rosa Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
May
1
Jun
1
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wedbush
Wells Fargo
Piper Sandler
JP Morgan
Credit Suisse

1calculated from analyst ratings

Analyst Ratings for Monte Rosa Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Monte Rosa Therapeutics (GLUE) stock?

A

The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by Wedbush on September 12, 2024. The analyst firm set a price target for $11.00 expecting GLUE to rise to within 12 months (a possible 84.87% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?

A

The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by Wedbush, and Monte Rosa Therapeutics reiterated their outperform rating.

Q

When was the last upgrade for Monte Rosa Therapeutics (GLUE)?

A

The last upgrade for Monte Rosa Therapeutics Inc happened on January 3, 2023 when Wells Fargo raised their price target to $19. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.

Q

When was the last downgrade for Monte Rosa Therapeutics (GLUE)?

A

There is no last downgrade for Monte Rosa Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

Q

Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?

A

While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a reiterated with a price target of $11.00 to $11.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $5.95, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch